ClinicalTrials.gg
CompletedNCT02752776PROSEUpdated Sep 25, 2019Results posted

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

A Phase 4 interventional study of Secukinumab in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 215 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,660
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Pruritus by Novartis — 2 open to participants now, 2 under way, 2 of them phase 3. Pruritus · Novartis.

Enrollment
Largest of 17
1,660 · median 182
Started
2016
the only one that year
Phase 4
2 of 17
none open now
Registered
7th of 17
by date

Among the 17 studies in Pruritus by Novartis, this one has the largest enrollment, is the only one that started in 2016, is one of 2 in phase 4, and was the 7th registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

2 of the 17 studies in Pruritus by Novartis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pruritus by Novartis, or all of them as a file.
02

Study summary

Study of effects of secukinumab 300 mg s.c. on quality of life (QoL) in psoriasis in patients with or without prior exposure to systemic therapy.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • secukinumab
  • AIN457
  • Moderate to severe plaque psoriasis
  • immune-mediated systemic disease
  • scaly patches
  • papules
  • plaques
  • itching
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged at least 18 years at time of Screening.
  • Moderate to severe plaque-type psoriasis diagnosed for at least 3 months prior to Screening and candidate for systemic therapy.
  • Other protocol defined inclusion criteria may apply. Please refer to the protocol.

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than moderate to severe plaque-type psoriasis, e.g. drug-induced psoriasis at Screening.
  • Patients with previous treatment with any agent targeting interleukin (IL)-17 directly or IL-17 receptor A (e.g. secukinumab, ixekizumab, or brodalumab).
  • Pregnant or nursing (lactating) women
  • Women of unless they use effective
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,660 participants (actual)

Study arms

  • Experimental
    Secukinumab

    All patients are received s.c. injections of secukinumab 300 mg at Week 0, 1, 2 and 3 during the first 4 weeks followed by monthly maintenance dosing of 300 mg secukinumab starting at Week 4 until Week 48. Consideration was given to discontinuing treatment in patients who showed no response up to 16 weeks of treatment (e.g. patients who did not achieve a PASI 50 response). If discontinued, patients completed the end of study visit assessments. Some patients with an initially partial response (e.g. patients who achieved a PASI 50 response but not a PASI 75 response) subsequently improved with continued treatment beyond 16 weeks.

    Drug: Secukinumab

Interventions

  • Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).

    Also known as: AIN457

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

    Time frame: 16 weeks

Secondary outcomes

  1. Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 52

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

    Time frame: 52 weeks

  2. Percentage of Participants in Each DLQI Score Category at Week 16 and Week 52

    The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

    Time frame: 52 weeks

  3. Percentage of Participants With PASI 50, PASI 75, PASI 90, PASI 100 or IGA Mod 2011 0/1 Response at Week 16 and 52

    PASI is a combined assessment of lesion severity \& affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself \& scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), \& severity is estimated by clinical signs, erythema, induration \& desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 \& 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

    Time frame: Week 16, Week 52

  4. Absolute Change From Baseline in EQ-5D-5L Crosswalk Index at Week 16 and Week 52

    The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort \& anxiety/depression. The 5 dimensions have 5 response levels scored from 1 (best) to 5 (worst). The first 3 dimensions have the response levels lasting from no problems, slight problems, moderate problems, severe problems to unable; the last 2 dimensions have the 5 response levels lasting from no, slight, moderate, severe to extreme. From these 5 dimensions the Crosswalk-index is calculated by concatenating the responses \& choosing the corresponding country specific index value from the EQ-5D-5L_Crosswalk_Index_Value_Calculator.v2 excel file (https://euroqol.org/eq-5d-instruments/eq-5d-5labout/valuation-standard-value-sets/crosswalk-index-value-calculator/). This calculated participant-level index scores from -0.654 (worst health) to 1.0 (best health).

    Time frame: Week 16, Week 52

  5. Absolute Change From Baseline in EQ-5D-5L Visual Analogue Scale (VAS) at Week 16 and Week 52

    A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled "best imaginable health state" and "worst imaginable health state." This resulted in a numeric value set ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state").

    Time frame: Week 16, Week 52

  6. Absolute Change From Baseline in HAQ-DI at Week 16 and Week 52

    The HAQ-DI (Health Assessment Questionnaire - Disability Index) assesses a patient's level of functional ability \& includes questions on fine movements of the upper extremity, locomotor activities of the lower extremity \& activities that involve both upper \& lower extremities. There are 20 items in 8 categories of functioning including dressing \& grooming, arising, eating, walking, hygiene, reach, grip \& usual activities. The stem of each item asks over the past week, "Are you able to..." perform a particular task. Each item is scored on a 4-point scale from 0 to 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) \& unable to do (3). The HAQ-DI also includes questions about the use of 'aids or devices' \& aid from other people to supplement the answers given to the 20 items. Total scores were calculated by averaging all scores and ranging from 0 (best) to 3 (worst). Subtracting the baseline value from the week 16 or 52 values results in the change.

    Time frame: Week 16 and Week 52

  7. Absolute Change From Baseline in Numeric Rating Scale (NRS) at Week 16 and Week 52

    Selfadministered 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching \& scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; \& Scaling: Overall, how severe was your psoriasis related scaling over the past 24 hours? Patients had to rate their pain, itching, \& scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) \& the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category.

    Time frame: 16 and 52 weeks

  8. Treatment Satisfaction Questionnaire for Medication (TSQM) Scale Scores at Week 16 and Week 52

    Treatment Satisfaction Questionnaire for Medication (TSQM) is general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.

    Time frame: 16 and 52 weeks

  9. Patient Benefit Index (PBI) at Week 16 and Week 52

    The questionnaire includes 23 items on patient-relevant therapy needs \& benefits. The first part of the instrument, the 'Patient Needs Questionnaire' (PNQ), is filled in by the patient before therapy. A 5-step Likert scale (0='not important at all' to 4='very important') records the individual relevance of the different items to the patients. The second part, the PBQ, is filled in by the patient during or after therapy. It comprises the same items as the PNQ, but in contrast, the patients evaluate the extent to which the treatment needs have been fulfilled by therapy (scaled from 0='treatment did not help at all' to 4='treatment helped a lot'). In addition, the Likert scale contains the option 'does not apply to me' in the PNQ \& the option 'did not apply to me' in the PBQ. The needs prior to treatment (PNQ) \& the benefits achieved by treatment (PBQ) are converted to a weighted index value, the PBI in the narrower sense. PBI can have a value from 0='no benefit' to 4='maximal benefit'.

    Time frame: Week 16 and Week 52

07

Results

Posted Sep 25, 2019

Participant flow

A total of 1660 participants were treated and included in the Safety set.

Participant flow — Overall Study
MilestoneSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)
Started663673324
Completed611597276
Not completed527648
Withdrew: Adverse event152311
Withdrew: Lack of efficacy2614
Withdrew: Lost to follow-up11124
Withdrew: Non-compliance with study treatment001
Withdrew: Physician decision262
Withdrew: Pregnancy163
Withdrew: Protocol violation10136
Withdrew: Subject/guardian decision864
Withdrew: Death001
Withdrew: Withdrawal by subject342

Outcome measures

PrimaryPercentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

Time frame:
16 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16
Percentage of participantsSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 1674.7 (71.2 to 78.0)71.3 (67.7 to 74.7)61.7 (56.1 to 67.0)70.8 (68.5 to 73.0)
SecondaryPercentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 52

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

Time frame:
52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 52
Percentage of participantsSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 5275.3 (71.7 to 78.5)73.3 (69.8 to 76.6)62.0 (56.5 to 67.3)71.9 (69.6 to 74.0)
SecondaryPercentage of Participants in Each DLQI Score Category at Week 16 and Week 52

The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment.

Time frame:
52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants in Each DLQI Score Category at Week 16 and Week 52
Percentage of participantsSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Wk 16: DLQI cat. score: 2-518.3 (15.5 to 21.6)19.1 (16.2 to 22.3)21.2 (16.9 to 26.2)19.2 (17.3 to 21.2)
Wk 16: DLQI cat. score: 6-105.7 (4.1 to 7.8)6.3 (4.6 to 8.5)9.3 (6.5 to 13.2)6.7 (5.5 to 8.0)
Wk 16: DLQI cat. score: 11-201.2 (0.6 to 2.5)2.9 (1.8 to 4.5)5.3 (3.2 to 8.5)2.7 (2.0 to 3.6)
Wk 16:DLQI cat. score: 21-300.0 (0.0 to 0.7)0.5 (0.1 to 1.4)2.5 (1.2 to 5.0)0.7 (0.4 to 1.2)
Wk 52: DLQI cat. score: 2-517.9 (15.0 to 21.1)14.0 (11.5 to 16.9)18.2 (14.2 to 23.0)16.4 (14.6 to 18.3)
Wk 52: DLQI cat. score: 6-104.7 (3.3 to 6.7)7.2 (5.4 to 9.4)9.6 (6.7 to 13.4)6.7 (5.5 to 8.0)
Wk 52:DLQI cat. score: 11-201.8 (1.0 to 3.3)4.0 (2.7 to 5.9)8.3 (5.7 to 12.0)4.0 (3.1 to 5.1)
Wk 52:DLQI cat. score: 21-300.3 (0.1 to 1.2)1.5 (0.8 to 2.8)1.9 (0.8 to 4.2)1.1 (0.7 to 1.8)
SecondaryPercentage of Participants With PASI 50, PASI 75, PASI 90, PASI 100 or IGA Mod 2011 0/1 Response at Week 16 and 52

PASI is a combined assessment of lesion severity \& affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs); each area is scored by itself \& scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), \& severity is estimated by clinical signs, erythema, induration \& desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area\* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 \& 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.

Time frame:
Week 16, Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With PASI 50, PASI 75, PASI 90, PASI 100 or IGA Mod 2011 0/1 Response at Week 16 and 52
Percentage of participantsSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Wk 16: PASI 5097.7 (96.2 to 98.7)97.5 (95.9 to 98.5)95.0 (91.9 to 97.2)97.1 (96.1 to 97.8)
Wk 16: PASI 7594.4 (92.3 to 96.0)92.8 (90.5 to 94.7)85.4 (81.0 to 89.1)92.0 (90.6 to 93.3)
Wk 16: PASI 9082.4 (79.2 to 85.2)78.8 (75.5 to 81.8)69.0 (63.6 to 74.0)78.3 (76.2 to 80.3)
Wk 16: PASI 10047.3 (43.4 to 51.2)38.8 (35.1 to 42.6)33.4 (28.4 to 38.9)41.1 (38.7 to 43.6)
Wk 16: IGA 0/187.4 (84.5 to 89.8)84.9 (82.0 to 87.5)76.2 (71.1 to 80.7)84.2 (82.3 to 85.9)
Wk 52: PASI 5097.9 (96.4 to 98.9)96.3 (94.5 to 97.6)92.9 (89.4 to 95.5)96.3 (95.2 to 97.1)
Wk 52: PASI 7594.4 (92.3 to 96.0)89.7 (87.1 to 91.9)83.3 (78.7 to 87.2)90.4 (88.8 to 91.7)
Wk 52: PASI 9080.8 (77.6 to 83.7)75.5 (72.0 to 78.7)63.9 (58.4 to 69.1)75.3 (73.2 to 77.4)
Wk 52: PASI 10056.9 (53.1 to 60.8)45.5 (41.7 to 49.3)37.0 (31.8 to 42.6)48.4 (46.0 to 50.8)
Wk 52: IGA 0/186.4 (83.5 to 88.9)79.9 (76.7 to 82.9)71.3 (66.0 to 76.1)80.8 (78.8 to 82.7)
SecondaryAbsolute Change From Baseline in EQ-5D-5L Crosswalk Index at Week 16 and Week 52

The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort \& anxiety/depression. The 5 dimensions have 5 response levels scored from 1 (best) to 5 (worst). The first 3 dimensions have the response levels lasting from no problems, slight problems, moderate problems, severe problems to unable; the last 2 dimensions have the 5 response levels lasting from no, slight, moderate, severe to extreme. From these 5 dimensions the Crosswalk-index is calculated by concatenating the responses \& choosing the corresponding country specific index value from the EQ-5D-5L_Crosswalk_Index_Value_Calculator.v2 excel file (https://euroqol.org/eq-5d-instruments/eq-5d-5labout/valuation-standard-value-sets/crosswalk-index-value-calculator/). This calculated participant-level index scores from -0.654 (worst health) to 1.0 (best health).

Time frame:
Week 16, Week 52
Reported as:
Mean · scores on a scale
Absolute Change From Baseline in EQ-5D-5L Crosswalk Index at Week 16 and Week 52
scores on a scaleSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Week 160.217 ± 0.22940.201 ± 0.22770.235 ± 0.26020.214 ± 0.2352
Week 520.221 ± 0.23530.193 ± 0.23600.226 ± 0.25960.211 ± 0.2408
SecondaryAbsolute Change From Baseline in EQ-5D-5L Visual Analogue Scale (VAS) at Week 16 and Week 52

A visual analogue scale (VAS) was used within the EQ-5D. This scale recorded the respondent's self-rated health on a vertical 20-cm VAS where the endpoints were labeled "best imaginable health state" and "worst imaginable health state." This resulted in a numeric value set ranging from 0 (="worst imaginable health state") up to 100 (="best imaginable health state").

Time frame:
Week 16, Week 52
Reported as:
Mean · scores on a scale
Absolute Change From Baseline in EQ-5D-5L Visual Analogue Scale (VAS) at Week 16 and Week 52
scores on a scaleSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Week 1619.7 ± 24.3621.4 ± 25.6618.7 ± 26.6620.2 ± 25.36
Week 5221.7 ± 24.1122.6 ± 25.4719.5 ± 25.1421.7 ± 24.88
SecondaryAbsolute Change From Baseline in HAQ-DI at Week 16 and Week 52

The HAQ-DI (Health Assessment Questionnaire - Disability Index) assesses a patient's level of functional ability \& includes questions on fine movements of the upper extremity, locomotor activities of the lower extremity \& activities that involve both upper \& lower extremities. There are 20 items in 8 categories of functioning including dressing \& grooming, arising, eating, walking, hygiene, reach, grip \& usual activities. The stem of each item asks over the past week, "Are you able to..." perform a particular task. Each item is scored on a 4-point scale from 0 to 3, representing normal, no difficulty (0), some difficulty (1), much difficulty (2) \& unable to do (3). The HAQ-DI also includes questions about the use of 'aids or devices' \& aid from other people to supplement the answers given to the 20 items. Total scores were calculated by averaging all scores and ranging from 0 (best) to 3 (worst). Subtracting the baseline value from the week 16 or 52 values results in the change.

Time frame:
Week 16 and Week 52
Reported as:
Mean · scores on a scale
Absolute Change From Baseline in HAQ-DI at Week 16 and Week 52
scores on a scaleSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Week 16-0.7 ± 0.97-0.5 ± 0.83-0.3 ± 0.85-0.5 ± 0.87
Week 52-0.7 ± 0.90-0.5 ± 0.90-0.4 ± 0.85-0.5 ± 0.88
SecondaryAbsolute Change From Baseline in Numeric Rating Scale (NRS) at Week 16 and Week 52

Selfadministered 11-point numeric rating scales (NRS, 0-10) were used to evaluate the patients' assessment of their current pain, itching \& scaling. Respondents answered the following questions for the assessment: Pain: Overall, how severe was your psoriasis-related pain over the past 24 hours?; Itching: Overall, how severe was your psoriasis-related itch over the past 24 hours?; \& Scaling: Overall, how severe was your psoriasis related scaling over the past 24 hours? Patients had to rate their pain, itching, \& scaling from 0 to 10 (11-point scale), with the understanding that the 0 represents the absence or null end of the pain, itching, or scale intensity (i.e. no pain, itching or scaling) \& the 10 represents the other extreme of pain, itching, or scaling intensity (i.e. pain, itching or scaling as bad as it could be). The number that the patient selected represents his or her intensity score in the respective category.

Time frame:
16 and 52 weeks
Reported as:
Mean · scores on a scale
Absolute Change From Baseline in Numeric Rating Scale (NRS) at Week 16 and Week 52
scores on a scaleSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Pain: Wk 16-3.0 ± 2.87-3.3 ± 3.11-3.3 ± 3.30-3.2 ± 3.06
Pain: Wk 52-3.1 ± 2.95-3.2 ± 3.22-3.3 ± 3.36-3.2 ± 3.14
Itching: Wk 16-4.9 ± 2.96-4.9 ± 3.06-4.8 ± 3.31-4.9 ± 3.07
Itching: Wk 52-5.0 ± 2.92-5.0 ± 3.10-4.6 ± 3.28-4.9 ± 3.07
Scaling: Wk 16-5.5 ± 2.68-5.5 ± 2.71-5.2 ± 3.26-5.4 ± 2.81
Scaling: Wk 52-5.4 ± 2.72-5.3 ± 2.87-4.9 ± 3.27-5.3 ± 2.90
SecondaryTreatment Satisfaction Questionnaire for Medication (TSQM) Scale Scores at Week 16 and Week 52

Treatment Satisfaction Questionnaire for Medication (TSQM) is general measure for treatment satisfaction. Each scale score was calculated by summing individual items and then transformed to a 0-100 scale. Higher summary scores indicate better satisfaction with study drug.

Time frame:
16 and 52 weeks
Reported as:
Mean · scores on a scale
Treatment Satisfaction Questionnaire for Medication (TSQM) Scale Scores at Week 16 and Week 52
scores on a scaleSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Effectiveness: Wk 1681.5 ± 24.0280.9 ± 25.1375.0 ± 23.4380.0 ± 24.48
Effectiveness: Wk 5285.1 ± 20.6482.0 ± 25.0574.9 ± 24.2481.9 ± 23.50
Convenience: Wk 1679.2 ± 15.5080.8 ± 15.8375.9 ± 15.2079.2 ± 15.67
Convenience: Wk 5282.8 ± 15.6783.9 ± 15.4278.9 ± 15.1482.5 ± 15.57
Global satisfaction: Wk 1683.8 ± 14.7183.3 ± 16.6875.1 ± 20.0781.9 ± 16.99
Global satisfaction: Wk 5283.9 ± 17.2381.9 ± 20.3873.5 ± 23.1081.1 ± 20.14
SecondaryPatient Benefit Index (PBI) at Week 16 and Week 52

The questionnaire includes 23 items on patient-relevant therapy needs \& benefits. The first part of the instrument, the 'Patient Needs Questionnaire' (PNQ), is filled in by the patient before therapy. A 5-step Likert scale (0='not important at all' to 4='very important') records the individual relevance of the different items to the patients. The second part, the PBQ, is filled in by the patient during or after therapy. It comprises the same items as the PNQ, but in contrast, the patients evaluate the extent to which the treatment needs have been fulfilled by therapy (scaled from 0='treatment did not help at all' to 4='treatment helped a lot'). In addition, the Likert scale contains the option 'does not apply to me' in the PNQ \& the option 'did not apply to me' in the PBQ. The needs prior to treatment (PNQ) \& the benefits achieved by treatment (PBQ) are converted to a weighted index value, the PBI in the narrower sense. PBI can have a value from 0='no benefit' to 4='maximal benefit'.

Time frame:
Week 16 and Week 52
Reported as:
Mean · scores on a scale
Patient Benefit Index (PBI) at Week 16 and Week 52
scores on a scaleSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Week 163.5 ± 0.613.4 ± 0.693.2 ± 0.853.4 ± 0.70
Week 523.5 ± 0.703.4 ± 0.803.2 ± 0.963.4 ± 0.80

Adverse events

Collected over All Adverse Events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit for up to 52 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subpopulation A (Naive)0/663 (0%)43/663 (6.5%)450/663 (67.9%)
Subpopulation B (Non-biologic)0/673 (0%)44/673 (6.5%)474/673 (70.4%)
Subpopulation C (Biologic)1/324 (0.3%)32/324 (9.9%)203/324 (62.7%)
All Participants1/1,660 (0.1%)119/1,660 (7.2%)1,127/1,660 (67.9%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
Ischaemic strokeNervous system disorders0/6630/6733/3243/1660
Pelvic fractureInjury, poisoning and procedural complications0/6630/6732/3242/1660
NephrolithiasisRenal and urinary disorders0/6631/6732/3243/1660
PsoriasisSkin and subcutaneous tissue disorders1/6632/6732/3245/1660
ErysipelasInfections and infestations4/6632/6730/3246/1660
Crohn's diseaseGastrointestinal disorders1/6633/6730/3244/1660
Angina pectorisCardiac disorders1/6630/6731/3242/1660
Cardiac failureCardiac disorders0/6630/6731/3241/1660
VertigoEar and labyrinth disorders0/6630/6731/3241/1660
Pupils unequalEye disorders0/6630/6731/3241/1660
Most frequent other events
Showing 10 of 38
Most frequent other events
EventSubpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)All Participants
NasopharyngitisInfections and infestations189/663189/67366/324444/1660
HeadacheNervous system disorders76/66379/67321/324176/1660
Back painMusculoskeletal and connective tissue disorders31/66346/67315/32492/1660
PsoriasisSkin and subcutaneous tissue disorders20/66336/67322/32478/1660
Upper respiratory tract infectionInfections and infestations39/66325/67320/32484/1660
PruritusSkin and subcutaneous tissue disorders31/66341/67313/32485/1660
Oropharyngeal painRespiratory, thoracic and mediastinal disorders34/66340/67314/32488/1660
RhinitisInfections and infestations37/66337/67311/32485/1660
CoughRespiratory, thoracic and mediastinal disorders37/66331/67312/32480/1660
ArthralgiaMusculoskeletal and connective tissue disorders26/66328/67318/32472/1660

Baseline characteristics

Safety set: The Safety set included all patients who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Subpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)Total
Mean43.2 ± 14.0344.4 ± 13.6747.4 ± 12.8944.5 ± 13.74
Sex: Female, Male
Sex: Female, Male(Participants)Subpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)Total
Female224222107553
Male4394512171107
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Subpopulation A (Naive)Subpopulation B (Non-biologic)Subpopulation C (Biologic)Total
Caucasian6266423071575
Black3205
Asian126220
Other22231560
08

Study locations

215 sites
  • Novartis Investigative Site
    Geel, BEL 2440, Belgium
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Seraing, 4100, Belgium
  • Novartis Investigative Site
    Pleven, 5800, Bulgaria
  • Novartis Investigative Site
    Sofia, 1407, Bulgaria
  • Novartis Investigative Site
    Sofia, 1431, Bulgaria
  • Novartis Investigative Site
    Stara Zagora, 6000, Bulgaria
  • Novartis Investigative Site
    Varna, 9010, Bulgaria
  • Novartis Investigative Site
    Usti nad Labem, Czech Republic 400 11, Czechia
  • Novartis Investigative Site
    Plzen, 30460, Czechia
  • Novartis Investigative Site
    Praha 5, 150 06, Czechia
  • Novartis Investigative Site
    Praha, 12808, Czechia
  • Novartis Investigative Site
    Tallinn, 10138, Estonia
  • Novartis Investigative Site
    Tallinn, 13419, Estonia
  • Novartis Investigative Site
    Tartu, 51014, Estonia
  • Novartis Investigative Site
    Le Mans, Cedex 09 72037, France
  • Novartis Investigative Site
    Toulon Cedex 9, Val De Marne 83800, France
  • Novartis Investigative Site
    Angers cedex 09, 49933, France
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Argenteuil, 95107, France
  • Novartis Investigative Site
    Auxerre, 89000, France
  • Novartis Investigative Site
    Bayonne, 64109, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Boulogne-sur-Mer, 62321, France
  • Novartis Investigative Site
    Brest, 29609, France
  • Novartis Investigative Site
    Caen, 14033, France
  • Novartis Investigative Site
    Cannes, 06400, France
  • Novartis Investigative Site
    Clermont Ferrand cedex 1, 63003, France
  • Novartis Investigative Site
    Dijon, 21000, France
  • Novartis Investigative Site
    Grenoble Cedex, France
  • Novartis Investigative Site
    La Rochelle, 17019, France
  • Novartis Investigative Site
    Lille, 59000, France
  • Novartis Investigative Site
    Marseille cedex 05, 13385, France
  • Novartis Investigative Site
    Martigues, 13500, France
  • Novartis Investigative Site
    Montpellier cedex 5, 34295, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Nimes, 30029, France
  • Novartis Investigative Site
    Pierre Benite Cedex, 69495, France
  • Novartis Investigative Site
    Pringy cedex, 74374, France
  • Novartis Investigative Site
    Quimper, 29000, France
  • Novartis Investigative Site
    Reims, 51100, France
  • Novartis Investigative Site
    Rouen Cedex, 76031, France
  • Novartis Investigative Site
    Saint Mande, 94163, France
  • Novartis Investigative Site
    St Priest en Jarez Cedex, 42277, France
  • Novartis Investigative Site
    Toulouse Cedex, 31400, France
  • Novartis Investigative Site
    Valence Cedex 9, 26953, France
  • Novartis Investigative Site
    Valenciennes Cedex, 59322, France
  • Novartis Investigative Site
    Vandoeuvre Les Nancy, 54511, France
  • Novartis Investigative Site
    Mannheim, Baden-Wuerttemberg 68305, Germany
  • Novartis Investigative Site
    Muenchen, Bayern 81675, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Andernach, 56626, Germany
  • Novartis Investigative Site
    Berlin, 10789, Germany
  • Novartis Investigative Site
    Berlin, 13187, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Berlin, 13507, Germany
  • Novartis Investigative Site
    Berlin, 13597, Germany
  • Novartis Investigative Site
    Berlin, 15831, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Bramsche, 49565, Germany
  • Novartis Investigative Site
    Braunschweig, 38114, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigative Site
    Friedrichshafen, 88045, Germany
  • Novartis Investigative Site
    Gelsenkirchen, 45883, Germany
  • Novartis Investigative Site
    Gera, 07548, Germany
  • Novartis Investigative Site
    Halle, 06108, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Hamburg, 22303, Germany
  • Novartis Investigative Site
    Hamburg, 22391, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Ibbenbueren, 49477, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 50937, Germany
  • Novartis Investigative Site
    Lubeck, 23538, Germany
  • Novartis Investigative Site
    Ludwigshafen am Rhein, 67063, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Osnabrueck, 49074, Germany
  • Novartis Investigative Site
    Pommelsbrunn, 91224, Germany
  • Novartis Investigative Site
    Quedlinburg, 06484, Germany
  • Novartis Investigative Site
    Recklinghausen, 45657, Germany
  • Novartis Investigative Site
    Schwerin, 19055, Germany
  • Novartis Investigative Site
    Simmern, 55469, Germany
  • Novartis Investigative Site
    Vechta, 49377, Germany
  • Novartis Investigative Site
    Wiesbaden, 65203, Germany
  • Novartis Investigative Site
    Athens, GR 115 25, Greece
  • Novartis Investigative Site
    Heraklion Crete, 711 10, Greece
  • Novartis Investigative Site
    Patras, 265 00, Greece
  • Novartis Investigative Site
    Afula, 1834111, Israel
  • Novartis Investigative Site
    Be'er Sheva, 84101, Israel
  • Novartis Investigative Site
    Jerusalem, 91120, Israel
  • Novartis Investigative Site
    Kfar Saba, 4428164, Israel
  • Novartis Investigative Site
    Petach Tikva, 4941492, Israel
  • Novartis Investigative Site
    Arezzo, AR 52100, Italy

Showing the first 100 of 215 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Merola JF, McInnes IB, Deodhar AA, Dey AK, Adamstein NH, Quebe-Fehling E, Aassi M, Peine M, Mehta NN. Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications. Rheumatol Ther. 2022 Jun;9(3):935-955. doi: 10.1007/s40744-022-00434-z. Epub 2022 Mar 19. PubMed 35305260 ↗
  • da Silva N, Sommer R, Ortmann CE, Jagiello P, Bachhuber T, Augustin M. Secukinumab effects on disease burden, patient needs and benefits, and treatment satisfaction in patients with plaque psoriasis across European regions: patient perspective data from the PROSE study. J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2241-2249. doi: 10.1111/jdv.17525. Epub 2021 Jul 31. PubMed 34273904 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Supporting information: Study protocol, Statistical analysis plan

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Mar 2018, 24 months.

Results were first posted in Sep 2019, 1 year 5 months after primary completion.

Of 19 phase 4 interventional studies under Pruritus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 33. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2016
First posted
Apr 27, 2016
StartActual
Mar 17, 2016
Primary completionActual
Mar 28, 2018
CompletionActual
Mar 28, 2018
Results first posted
Sep 25, 2019
Last update
Sep 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02752776
Responsible party
Sponsor
First posted
Apr 27, 2016
Start date
Mar 17, 2016
Primary completion
Mar 28, 2018
Completion
Mar 28, 2018
Results posted
Sep 25, 2019
Last update
Sep 25, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion